Antineoplastic Agents, Alkylating

"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Descriptor ID	D018906
MeSH Number(s)	D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
Concept/Terms	Antineoplastic Agents, Alkylating Antineoplastic Agents, Alkylating Alkylating Antineoplastic Agents Alkylating Antineoplastic Drugs Alkylating Antineoplastics Antineoplastic Alkylating Agents Antineoplastic Drugs, Alkylating Antineoplastics, Alkylating Alkylating Agents, Antineoplastic Alkylating Drugs, Antineoplastic Antineoplastic Alkylating Drugs Drugs, Antineoplastic Alkylating

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Alkylating Agents [D27.505.519.124]
Antineoplastic Agents, Alkylating [D27.505.519.124.035]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Alkylating [D27.505.954.248.150]
Toxic Actions [D27.888]
Noxae [D27.888.569]
Alkylating Agents [D27.888.569.035]
Antineoplastic Agents, Alkylating [D27.888.569.035.035]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Alkylating".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.

Bar chart showing 22 publications over 12 distinct years, with a maximum of 3 publications in 2014 and 2015 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	2	0	2
2003	1	0	1
2004	1	0	1
2006	0	1	1
2010	1	1	2
2012	1	1	2
2014	1	2	3
2015	2	1	3
2016	2	1	3
2017	0	1	1
2018	1	0	1
2020	1	1	2

Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.

Das A, Alshareef M, Porto GBF, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. J Neurol Sci. 2020 Nov 15; 418:117102.

View in: PubMed
Das A, Henderson FC, Alshareef M, Porto GBF, Kanginakudru I, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D. MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol. 2021 Mar; 23(3):612-619.

View in: PubMed
Ward SM, Skinner M, Saha B, Emrick T. Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. Mol Pharm. 2018 11 05; 15(11):5263-5276.

View in: PubMed
Cai YS, Sarotti AM, G?ndisch D, Kondratyuk TP, Pezzuto JM, Turkson J, Cao S. Heliotropiumides A and B, new phenolamides with N-carbamoyl putrescine moiety from Heliotropium foertherianum collected in Hawaii and their biological activities. Bioorg Med Chem Lett. 2017 10 15; 27(20):4630-4634.

View in: PubMed
Voorhees PM, Usmani SZ. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Clin Adv Hematol Oncol. 2016 Sep; 14(9):719-28.

View in: PubMed
Kamiya-Matsuoka C, Cachia D, Waguespack SG, Crane CH, Mahajan A, Brown PD, Nam JY, McCutcheon IE, Penas-Prado M. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. Pituitary. 2016 Aug; 19(4):415-21.

View in: PubMed
Strickland BA, Cachia D, Jalali A, Cykowski MD, Penas-Prado M, Langford LA, Li J, Shah K, Weinberg JS. Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. Neurosurgery. 2016 Mar; 78(3):E466-73.

View in: PubMed
D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 Nov 10; 33(32):3741-9.

View in: PubMed
Kim J, Lee IH, Cho HJ, Park CK, Jung YS, Kim Y, Nam SH, Kim BS, Johnson MD, Kong DS, Seol HJ, Lee JI, Joo KM, Yoon Y, Park WY, Lee J, Park PJ, Nam DH. Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell. 2015 Sep 14; 28(3):318-28.

View in: PubMed
Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, Nayak L, Christianson LW, Horvath MC, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Alexander BM. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals